Skip to main content
Premium Trial:

Request an Annual Quote

Cofactor Genomics, NCI Partner to Validate RNA-Based Immune Profiling Assay

NEW YORK (GenomeWeb) – Cofactor Genomics announced today that it has partnered with the National Cancer Institute (NCI), in addition to agreements with three other unnamed academic and pharma groups, to demonstrate the clinical utility of Cofactor's RNA-based immune-profiling assay, Cofactor Paragon.

Under the terms of their material transfer agreement, the collaborators will use clinical specimens from several of NCI's clinical trials to validate the Paragon assay.

Cofactor's research collaborations will focus on applying Paragon to further understand the immune profiles of patients with conditions including sarcoma, prostate cancer, lung cancer, breast cancer, and bladder cancer as initial case studies.

"There is a need for advanced assays which enable thorough molecular tumor profiling to better predict and interpret patient response," James Gully, head of the immunotherapy section of the Genitourinary Malignancies Branch at the NCI Center for Cancer Research, said in a statement.

Cofactor will process the majority of the studies' samples in its St Louis-based laboratories, which include a CAP-accredited RNA sequencing facility. The data and feedback from the studies will allow Cofactor to shift the assay to an off-the-shelf sequencing kit, with complementary cloud-based informatics.

The firm believes that its approach will improve existing technologies by delivering RNA-based data in a simplified report.

Additional terms of the deal were not disclosed.

In September 2017, Cofactor Genomics raised $18 million in Series A funding.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.